ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. |
|
|
| Recruiting | 3 | 260 | Europe, Canada, US, RoW | Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone | Sanofi | Chronic Graft Versus Host Disease | 09/28 | 09/28 | | |
| Active, not recruiting | 1/2 | 46 | Canada, US | Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal | St. Jude Children's Research Hospital, Pfizer, Ipsen | Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma | 12/25 | 12/25 | | |
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL |
|
|
| Recruiting | 1 | 36 | Canada, US, RoW | Marqibo | Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc | ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute | 08/21 | 12/22 | | |
